EFFICACY AND SAFETY OF MOMETASONE FUROATE IN CHILDREN WITH ATOPIC DERMATITIS IN KAZAKHSTAN
Background. Atopic dermatitis is a serious chronic skin disease, often aggravated by the presence of microorganisms, which often responds well to strong corticosteroid therapy. However, long-term use of strong topical corticosteroids is associated with side effects such as skin atrophy. The current standard of local anti-inflammatory treatment is topical glucocorticosteroids and calcineurin inhibitors. Mometasone furoate 0.1 percent is a moderate efficacy corticosteroid, which is indicated for the treatment of atopic dermatitis in children. This research aims to evaluate the efficacy and safety of mometasone furoate in pediatric patients with atopic dermatitis.
Materials and methods. In this prospective trial, 60 pediatric patients diagnosed with mild to moderate AD were randomly assigned to two separate groups for comparison. The observation group (n=30) received treatment with 0.1% mometasone furoate, while the control group (n=30) underwent standard therapy without mometasone furoate. The study duration was 12 weeks and was conducted at San-Med Service Clinic in Shymkent, Kazakhstan, from December 1, 2024, to February 2025.
Results. Treatment with 0.1% mometasone furoate resulted in a more pronounced reduction in atopic dermatitis severity and greater improvement in quality of life (CDLQI) compared to standard therapy. The safety profile was favorable, with no significant adverse effects. Cortisol levels showed no statistically significant differences between the groups, confirming the absence of systemic effects.
Conclusions. Consistently using a 0.1% mometasone furoate topically to treat mild to moderate atopic dermatitis in children older than 2 years decreased the frequency of relapses and the quantity of mometasone furoate prescribed. It was also safe and well tolerated by patients.
Number of Views: 2
Category of articles:
Original article
Bibliography link
Abdushukurova G., Auyelova A., Ashirov B.A. Efficacy and safety of mometasone furoate in children with atopic dermatitis in Kazakhstan // Nauka i Zdravookhranenie [Science & Healthcare]. 2025. Vol.27 (5), pp. 153-159. doi 10.34689/SH.2025.27.5.019Related publications:
GENETIC VARIANTS IN LIPID-ASSOCIATED GENES IN THE KAZAKHSTANI COHORT WITH ATHEROSCLEROSIS AND HYPERTRIGLYCERIDEMIA
CLONAL HEMATOPOIESIS WITH INDETERMINATE POTENTIAL IN TET2 AND DNMT3A AMONG KAZAKHSTANI INDIVIDUALS WITH ATHEROSCLEROTIC DISEASE
PRELIMINARY ANALYSIS AND ASSESSMENT OF THE HEALTH STATUS OF THE DESCENDANTS OF PERSONS EXPOSED TO RADIATION, LIVING IN THE BESKARAGAI DISTRICT OF THE ABAY REGION
PRELIMINARY ANALYSIS OF THE HEALTH STATUS AND RADIATION DOSES OF RESIDENTS OF THE ABAY DISTRICT OF THE ABAY REGION, WHO ARE DESCENDANTS OF PERSONS EXPOSED TO RADIATION DUE TO NUCLEAR WEAPONS TESTS
TRENDS AND DISPARITIES IN CANCER MORBIDITY IN KAZAKHSTAN: A REGIONAL AND AGE-BASED ANALYSIS FOR 2014-2024